Navigation Links
BioMarin to Present at the Wedbush Life Sciences Conference
Date:8/9/2011

NOVATO, Calif., Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces Second Quarter 2011 Financial Results
2. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
3. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
4. BioMarin to Present at the William Blair Growth Stock Conference
5. BioMarin to Present at the Jefferies Global Healthcare Conference
6. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
7. BioMarin Announces First Quarter 2011 Financial Results
8. BioMarin to Present at the Deutsche Bank Healthcare Conference
9. BioMarin to Present at the Barclays Global Healthcare Conference
10. BioMarin to Present at the Cowen Health Care Conference
11. BioMarin to Present at the Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016 The life of Dr. Jan Vilcek ... anything but ordinary.  Twists of fate, combined with sheer grit, ... the constraints of communist Czechoslovakia to New York ... on to make history by playing a key role in ... the world, Remicade.  Dr. Vilcek brings readers along his improbable ...
(Date:2/9/2016)... 2016 The new report "Global Anti-Bacterial Drugs Market Assessment ... Consulting group reveals that the North America ... 38.9% in 2014 that translated into revenues worth US$ 16,907.3 million. ... , Asia-Pacific , Latin America ... . The global anti-bacterial market is inclined towards ...
(Date:2/8/2016)... , Feb.8, 2016 Alzheimer Diagnostic ... Summary Medical Devices sector report , ... 2015" provides an overview of Alzheimer Diagnostic Tests ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... A man who has struggled to quit smoking, a man who has ... determined to find solutions to his problems – and he did. Now Nabat, a serial ... to introduce his breakthrough inventions to the world and better people's lives. His own experience ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest ... and 700 companies. Attendees also get to see the most incredible gardens and ... Home Show , at the Colorado Convention Center - 700 14th St. Denver CO, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
Breaking Medicine News(10 mins):